00000nam 2200000zi 4500 9.914232 CaOODSP 20230120155511 m o d f cr cn||||||||| 220808t20232023oncd ob f000 0 eng d 9780660449364 CaOODSP eng rda CaOODSP n-cn--- HP40-320/2022E-PDF Cost-effectiveness of palivizumab prophylaxis for respiratory syncytial virus (RSV) : a systematic review. [Ottawa] : Public Health Agency of Canada = Agence de la santé publique du Canada, 2023. ©2023 1 online resource (41 pages) : graphs text txt rdacontent computer c rdamedia online resource cr rdacarrier Cover title. "Publication date: January 2023." At head of title: An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI). Issued also in French under title: Rapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : un examen systématique. Includes bibliographical references (pages 15-18). "Palivizumab (PVZ) prophylaxis is used as passive immunization for respiratory syncytial virus (RSV). However, due to its high acquisition costs, the value of this intervention is unclear. The objective of this study was to systematically review the cost-effectiveness of PVZ prophylaxis compared to no prophylaxis in infants under 24 months of age"--Executive summary, page 3. Palivizumab Canada Cost effectiveness. Respiratory syncytial virus Canada. Infants Diseases Canada. Public Health Agency of Canada, issuing body. Rapport coût-efficacité de la prophylaxie par palivizumab pour le virus respiratoire syncytial (VRS) : (CaOODSP)9.914233 PDF 1.42 MB https://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-320-2022-eng.pdf 220361